The short version of regulatory status fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Various labs jointly conducted thousands of repetitive chromatographic experiments between 1988 and 1993. All group 5 elements and protactinium were extracted from concentrated hydrochloric acid; after mixing with lower concentrations of hydrogen chloride, small amounts of hydrogen fluoride were added to start selective re-extraction. Dubnium showed behavior different from that of tantalum but similar to that of niobium and its pseudohomolog protactinium at concentrations of hydrogen chloride below 12 moles per liter. This similarity to the two elements suggested that the formed complex was either DbOX−4 or [Db(OH)2X4]−. After extraction experiments of dubnium from hydrogen bromide into diisobutyl carbinol (2,6-dimethylheptan-4-ol), a specific extractant for protactinium, with subsequent elutions with the hydrogen chloride/hydrogen fluoride mix as well as hydrogen chloride, dubnium was found to be less prone to extraction than either protactinium or niobium. This was explained as an increasing tendency to form non‐extractable complexes of multiple negative charges. Further experiments in 1992 confirmed the stability of the +5 state: Db(V) was shown to be extractable from cation‐exchange columns with α‐hydroxyisobutyrate, like the group 5 elements and protactinium; Db(III) and Db(IV) were not. In 1998 and 1999, new predictions suggested that dubnium would extract nearly as well as niobium and better than tantalum from halide solutions, which was later confirmed. The first isothermal gas chromatography experiments were performed in 1992 with 262Db (half-life 35 seconds).
As part of a comprehensive modernization of German radiation protection law, which is largely based on Directive 2013/59/Euratom, the provisions of the X-Ray Ordinance have been incorporated into the revised Radiation Protection Ordinance. Among many other measures, contaminated food was withdrawn from the market on a large scale. Parents were strongly advised not to let their children play in sandboxes. Some of the contaminated sand was replaced. In 1989, the Federal Office for Radiation Protection was incorporated into the Ministry of the Environment. On April 30, 2003, a new precautionary radiation protection law was promulgated to implement two EU directives on the health protection of persons against the dangers of ionizing radiation during medical exposure. The protection of workers from optical radiation (infrared radiation (IR), visible light (VIS) and ultraviolet radiation (UV)), which falls under the category of non-ionizing radiation, is regulated by the Ordinance on the Protection of Workers from Artificial Optical Radiation of 19 July 2010. It is based on the EU Directive 2006/25/EC of April 27, 2006. On March 1, 2010, the "Act on the Protection of Humans from Non-Ionizing Radiation" (NiSG), BGBl. I p. 2433, came into force, according to which the use of sunbeds by minors has been prohibited since August 4, 2009, in accordance with § 4 NiSG [Network and Information Systems Security Ordinance – NIS Ordinance] (in German) A new Radiation Protection Act came into force in Germany on October 1, 2017.
=== Receptors === Innate immune system senses intact peptidoglycan and peptidoglycan fragments using numerous PRRs (pattern recognition receptors) that are secreted, expressed intracellularly or expressed on the cell surface.
Sources: en.wikipedia.org
[Zn[(S2P(OR)2]2]2 + 2 L → 2 LZn[(S2P(OR)2]2 The polymers [Zn[(S2P(OR)2]2]n (n > 1) have also been characterized. For example, zinc diethyldithiophosphate, Zn[(S2P(OEt)2]2, crystallizes as a polymers consisting of linear chains. Reaction of Zn[(S2P(OR)2]2 with additional zinc oxide gives rise to the oxygen-centered cluster, Zn4O[(S2P(OR)2]6, which adopts the structure seen for basic zinc acetate.
On multiple occasions the combined UNITA and SADF forces launched unsuccessful offensives which became bogged down in minefields along narrow avenues of approach and were abandoned when the attackers came under heavy fire from the Cuban and FAPLA artillerymen west of the Cuito River. The defenders' artillery was sited just beyond the maximum range of the South African artillery and on high ground which gave them a commanding view of the battlefield. This advantage, coupled with the proliferation of minefields, and heavily reinforced FAPLA-Cuban defensive positions rendered further attacks by the South African troops futile. Operations Hooper and Packer were terminated after the SADF had killed almost 700 FAPLA troops and destroyed about half of the Angolan brigades' remaining tanks and armoured vehicles. Cuba had suffered 42 dead and the loss of 6 tanks. South African casualties were relatively light: 13 dead and several dozen severely wounded. Three SADF tanks were also abandoned in a minefield, while most of the others were damaged beyond immediate repair or rendered unserviceable due to mechanical problems. UNITA suffered thousands of casualties, prompting accusations that its troops had been used as "cannon fodder" by the SADF. Cuban post-action reports claimed that UNITA insurgents had been sent through the minefields at gunpoint to clear the way for the South African armour.
nucleic acid A long, polymeric macromolecule made up of smaller monomers called nucleotides which are chemically linked to one another in a chain. Two specific types of nucleic acid, DNA and RNA, are common to all living organisms, serving to encode the genetic information governing the construction, development, and ordinary processes of all biological systems. This information, contained within the order or sequence of the nucleotides, is translated into proteins, which direct all of the chemical reactions necessary for life.
Sources: en.wikipedia.org
=== Pakistan === In Pakistan, the National Institute of Health (NIH) in Islamabad is the pioneer in laboratory sciences. The College of Medical Lab Technology (CMLT) of the NIH offers a two-year F.Sc degree in Medical Lab Technology (MLT). The previous two-year B.Sc. in MLT was discontinued and replaced by the four-year Bachelor Program in Medical Lab Sciences (MLS). The University of Health Sciences in Lahore also offers a four-year Bachelor program in MLS through approved colleges. The University of Lahore, University of Faisalabad, University of Sargodha, and Superior University in Lahore all offer a five-year Doctor of Medical Lab Sciences (DMLS) Program. Eligibility criteria for the four-year B.Sc. in MLS and the five-year Doctor of Medical Lab Sciences (DMLS) is the F.Sc. Pre-Medical.
=== On resin cyclization === Peptides can be cyclized on a solid support. A variety of cyclization reagents can be used such as HBTU/HOBt/DIEA, PyBop/DIEA, PyClock/DIEA. Head-to-tail peptides can be made on the solid support. The deprotection of the C-terminus at some suitable point allows on-resin cyclization by amide bond formation with the deprotected N-terminus. Once cyclization has taken place, the peptide is cleaved from resin by acidolysis and purified. The strategy for the solid phase synthesis of cyclic peptides is not limited to attachment through Asp, Glu or Lys side chains. Cysteine has a very reactive sulfhydryl group on its side chain. A disulfide bridge is created when a sulfur atom from one cysteine forms a single covalent bond with another sulfur atom from a second cysteine in a different part of the protein. These bridges help to stabilize proteins, especially those secreted from cells. Some researchers use modified cysteines using S-acetamidomethyl (Acm) to block the formation of the disulfide bond but preserve the cysteine and the protein's original primary structure.
Dalman et al. (2024) proposed the new name Tyrannosaurus mcraeensis for the holotype (NMMNH P-3698), referencing the McRae Group, the rock layers to which the Hall Lake Formation belongs. The holotype of T. mcraeensis is found in the strata that are around a few million years older than the accepted range of T. rex, which existed at the end of the Maastrichtian. The rock layers were initially estimated to date to between 72.7 and 70.9 Ma, correlating to the latest Campanian or earliest Maastrichtian. However, in a 2024 conference abstract, the specific stratigraphic layer which yielded T. mcraeensis was estimated to be younger than 69.0 ± 0.4 Ma and older than 66.0 Ma based on the sandstone from the same fossil locality, which would suggest that the age of T. mcraeensis is much closer to T. rex than previously thought. T. mcraeensis was estimated at 12 metres (39 ft) long, which is similar to the size of an adult T. rex. The two are distinguished by characters of the skull. Amongst these, the dentary of T. mcraeensis is proportionately longer and possesses a less prominent chin, and the lower jaw shallower than that of T. rex, suggesting a weaker bite. The teeth are likewise blunter and more laterally compressed, while the post orbital crests are less prominent. Likewise, the skeletal anatomy showcases shared characteristics with Tarbosaurus and Zhuchengtyrannus. The validity of T. mcraeensis was questioned by other researchers in 2025. Morrison and colleagues noted the uncertainty in the previous age estimate and argued that the inclusion of the titanosaurian fossil (cf.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.